Biocardia completes submission of cardiamp cell therapy system in heart failure to japan's pharmaceutical medical device agency

Sunnyvale, calif. , july 05, 2023 (globe newswire) -- biocardia®, inc. [nasdaq: bcda], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces it completed its submission of the cardiamp cell therapy system to japan's pharmaceutical and medical device agency (pmda) towards approval for the indication of ischemic heart failure with reduced ejection fraction (hfref). the formal consultation with pmda to review the submission is anticipated in approximately three months and will be biocardia's third consultation with pmda.
BCDA Ratings Summary
BCDA Quant Ranking